We Need Robust Nomenclature for Orthobiologics: Letter to Editor

Murray, Iain R.; Makaram, Navnit S; Sherman, Seth L.; Safran, Marc R.; LaPrade, Robert F.; Abrams, Geoffrey D.

doi:10.1177/0363546520947043

Cited by 6 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study demonstrated that biologics, specifically PRP, were consistently ranked as a leading focus area within each domain of meniscus science. This coincides well with current clinical practice apparent by the expanding use and global interest in utilizing biologics for treating an array of musculoskeletal disorders [34, 35, 42, 44, 47]. However, despite the increased interest and consensus for more research and development of biologics in meniscus science, the majority of respondents in this survey reported that biologics are currently not valuable for the treatment of meniscal injuries.…”

Section: Discussionsupporting

confidence: 73%

“…This study demonstrated that biologics, specifically PRP, were consistently ranked as a leading focus area [34,35,42,44,47]. However, despite the increased interest and consensus for more research and development of biologics in meniscus science, the majority of respondents in this survey reported that biologics are currently not valuable for the treatment of meniscal injuries.…”

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

The future of meniscus science: international expert consensus

et al. 2021

Self Cite

View full text Add to dashboard Cite

Purpose The purpose of this study was to evaluate the main focus areas for research and development for furthering the state of meniscus science in 2021. Methods An electronic survey including 10 questions was sent in a blind fashion to the faculty members of the 5th International Conference on Meniscus Science and Surgery. These faculty served as an expert consensus on the future of research and development areas of meniscus science. Survey responses were analyzed using descriptive statistics and ranking weighted averages were calculated to score survey questions. Results Of the 82 faculty, 76 (93%) from 18 different countries completed the survey (84% male, 16% female). The highest ranked future research and development focus areas were meniscus repair, biologics, osteotomy procedures, addressing meniscus extrusion, and the development of new therapies for the prevention of posttraumatic osteoarthritis. Currently, the most ‘valuable’ type of biologic reported for meniscus treatment was platelet-rich plasma. The main reported global research limitation was a lack of long-term clinical outcomes data. The most promising emerging medical technologies for improving meniscus science were 3-D printing, personalized medicine, and artificial implants. Conclusions This survey suggests that the future of meniscus science should be focused on meniscal preservation techniques through meniscus repair, addressing meniscal extrusion, and the use of orthobiologics. The lack of long-term clinical outcomes was the main reported research limitation globally for meniscus treatment. Future product development utilizing emerging medical technologies suggest the use of 3-D printing for meniscal transplants/scaffolds, personalized treatment, and bioengineering for artificial implants. Level of Evidence Level V.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 84%

The future of meniscus science: international expert consensus

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…To our knowledge this is the first study worldwide with a long term follow (> 4 years) of patients who suffer from severe degenerative osteoarthritis of the knee (grade III and grade IV) and underwent an injection of bone marrow aspirate concentrate (BMAC, also described as "MSCs, mesenchymal stem cells" or "stem cell therapy" 13,27 ).…”

Section: Discussionmentioning

confidence: 99%

Intra-articular injection of bone marrow aspirate concentrate (mesenchymal stem cells) in KL grade III and IV knee osteoarthritis: 4 year results of 37 knees

Pabinger,

Lothaller,

Kobinia

2024

Sci Rep

View full text Add to dashboard Cite

Cell based therapies are increasingly used and results of bone marrow aspirate concentrate (BMAC) show encouraging short- to middle term results, superior to hyaluronic acid and platelet rich plasma (PRP). Most studies describe patients with mild to moderate arthritis and results of patients with KL III and IV osteoarthritis of the knee are limited to short term evaluations. Hence, the aim of this prospective study was to investigate the mid-term outcome of BMAC injections in patients with severe osteoarthritis of the knee. The BMAC was retrieved from the iliac crest as previously published with the “reorientation technique” from the iliac crest in supine position in analgosedation and injected into the patients’ osteoarthritic knees. Patients were followed-up for 4 years. WOMAC, IKDC, SF 36 and walking distance were measured in a total of 37 participants. There was an improvement of IKDC and WOMAC from the first year onwards and a significant improvement beginning from year 2 up to the mid-term follow-up: IKDC increased significantly from 56 ± 12 (range 34–81) to 73 ± 13 (range 45–100), p < 0.001. WOMAC decreased significantly from 40 ± 23 (range 6–96) to 18 ± 18 (range 0–67), p < 0.001. 35 of 37 knees improved regarding IKDC and WOMAC score from the first to the last follow-up. Not a single protheses had to be implanted. Elaborate statistical analysis was done to exclude covariates and confounders (age, time, BMI,…). In summary, this is the first study on BMAC injections into 37 osteoarthritic knees with a 4-year follow up showing significant improvements in IKDC and WOMAC scores, and with a 95% success rate and significant improvement in walking distance.Clinical relevance Describes the 4-year outcome of BMAC injections for knees with severe osteoarthritis.

show abstract

“…To our knowledge this is the rst study worldwide with a long term follow (> 4 years) of patients who suffer from severe degenerative osteoarthritis of the knee (grade 3 and grade 4) and underwent an injection of bone marrow aspirate concentrate (BMAC, also described as "MSCs, mesenchymal stem cells" or "stem cell therapy" 13,27 ).…”

Section: Discussionmentioning

confidence: 99%

Intra-articular injection of bone marrow aspirate concentrate in end stage knee osteoarthritis: 4 year results of 37 knees

Pabinger,

Kobinia,

Lothaller

2023

Preprint

View full text Add to dashboard Cite

Purpose: Cell based therapies are increasingly used and results of bone marrow aspirate concentrate (BMAC) show encouraging short- to middle term results, superior to hyaluronic acid and platelet rich plasma (PRP). Most studies describe patients with mild to moderate arthritis and short term results of patients with severe osteoarthritis of the knee. Hence, the aim of this prospective study was to investigate the mid-term outcome of BMAC injections in patients with severe osteoarthritis of the knee. Methods: The BMAC was retrieved from the iliac crest as previously published with the “reorientation technique” from the iliac crest in prone position in sedoanalgesia and injected into the patients’ osteoarthritic knees. Patients were followed-up for 4 years. WOMAC, IKDC, SF 36 and walking distance were measured in a total of 37 participants. Results There was an improvement of IKDC and WOMAC from the first year onwards and a significant improvement beginning from year 2 up to the mid-term follow-up: IKDC increased significantly from 56±12 (range 34-81) to 73±13 (range 45-100), p<.001. WOMAC decreased significantly from 40±23 (range 6-96) to 18 ±18 (range 0-67), p<.001. 35 of 37 knees improved regarding IKDC and WOMAC score from the first to the last follow-up. Not a single protheses had to be implanted. Elaborate statistical analysis was done to exclude covariates and confounders (age, time, BMI,…) . Conclusion In summary, this is the first study on BMAC injections into 37 osteoarthritic knees with a 4- year follow up showing significant improvements in IKDC and WOMAC scores, and with a 95% success rate and significant improvement in walking distance. Level of Evidence: Level I

show abstract

We Need Robust Nomenclature for Orthobiologics: Letter to Editor

Cited by 6 publications

References 30 publications

The future of meniscus science: international expert consensus

The future of meniscus science: international expert consensus

Intra-articular injection of bone marrow aspirate concentrate (mesenchymal stem cells) in KL grade III and IV knee osteoarthritis: 4 year results of 37 knees

Intra-articular injection of bone marrow aspirate concentrate in end stage knee osteoarthritis: 4 year results of 37 knees

Contact Info

Product

Resources

About